Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Accumulated Expenses (2021 - 2025)

Biofrontera has reported Accumulated Expenses over the past 5 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $2.8 million for Q4 2025, up 15.53% from a year ago — trailing twelve months through Dec 2025 was $2.8 million (up 15.53% YoY), and the annual figure for FY2025 was $2.8 million, up 15.53%.
  • Accumulated Expenses for Q4 2025 was $2.8 million at Biofrontera, down from $3.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for BFRIW hit a ceiling of $5.6 million in Q4 2021 and a floor of $2.4 million in Q2 2025.
  • Median Accumulated Expenses over the past 5 years was $2.8 million (2025), compared with a mean of $3.7 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 55.36% in 2022 and later grew 15.53% in 2025.
  • Biofrontera's Accumulated Expenses stood at $5.6 million in 2021, then tumbled by 55.36% to $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then dropped by 2.88% to $2.4 million in 2024, then increased by 15.53% to $2.8 million in 2025.
  • The last three reported values for Accumulated Expenses were $2.8 million (Q4 2025), $3.0 million (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.